Tyrosine Kinase inhibitors
Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors
... Almost all patients who are treated with a TKI are subject to side-effects of the given drug, varying from modest to severe side effects for which treatment needs to be discontinued or even stopped. The last two chapters ...
187
Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors
... Almost all patients who are treated with a TKI are subject to side-effects of the given drug, varying from modest to severe side effects for which treatment needs to be discontinued or even stopped. The last two chapters ...
187
Thyroid dysfunctions induced. by tyrosine kinase inhibitors.
... 18. Benvenga S, Ruggeri RMN, Trimarchi F. Thyroid and drugs. In: Thyroid diseases. Monaco F (ed), CRC, Coca Raton, 2012; pages 469-92 19. Sodergren SC, White A, Efficace F, et al. Systematic review of the side effects ...
36
A Review on Newer Tyrosine Kinase Inhibitors and their Uses
... [Table/Fig-1]. Tyrosine Kinase Inhibitors Undergoing Trials: BRIGATINIB: Brigatinib is an investigational target anti cancer drug that is under development for treatment of ALK positive NSCLC ...
6
ABL tyrosine kinase inhibitors (TKIs), and the management of their
... with tyrosine kinase inhibitors Before the introduction of the TKIs, the treatment of CML included hydroxyurea, interferon alpha (IFN-α), low-dose cytarabine and allogeneic haematopoietic stem cell ...
7
Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
... Abstract Tyrosine kinase inhibitors (TKIs) have rapidly become an established factor in oncology, and have been shown to be effective in a wide variety of solid and hematologic ...pump ...
6
Differential effects of tyrosine kinase inhibitors in haemostasis, thrombosis and inflammation
... novel tyrosine kinase inhibitors (TKIs), such as imatinib that particularly interfere with the ATP binding pocket of the Abl kinase domain of the Bcr-Abl ...
260
CiteSeerX — Epidermal growth factor receptor tyrosine kinase inhibitors
... tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches have been developed, humanised monoclonal antibodies and tyrosine kinase ...EGFR tyrosine ...
6
Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?
... Keywords: tyrosine kinase inhibitors; hepatic fibrosis; hepatotoxicity Received: July 02, 2016 Accepted: August 29, 2016 Published: August 31, 2016 ABSTRACT Aberrant activity of tyrosine ...
11
Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
... update of > 1800 patients (Pts) in the WORLD CML Registry. ASH Annual Meeting Abstracts 2012;120:3750. 57. Falchi L, Kantarjian HM, Quintas-Cardama A, O’Brien S, Jabbour EJ, Ravandi F, Borthakur G, Garcia-Manero G, ...
9
Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
... Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This is the case of ...
5
Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies
... Raf kinase (BRAF) mutation, mesenchymal-epithelial transition factor (MET) amplification and Excision repair cross-complementing group 1 (ERCC1) can be used to see whether there are any genetic mutations that lead ...
9
HER2 therapy Small molecule HER 2 tyrosine kinase inhibitors
... molecule tyrosine kinase inhibitors that compete with ATP binding at the cytoplasmic catalytic kinase domain of HER-2 block autophosphorylation and activation of HER-2, resulting in inhibition ...
8
Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer
... the tyrosine kinase domain of EGFR and increased activity of the EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, has become well ...
6
A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
... multiforme, tyrosine kinase inhibitors, invasion, Met, SRC Received: April 23, 2015 Accepted: October 06, 2015 Published: October 16, 2015 ABSTRACT Glioblastoma multiforme (GBM) is the most common ...
17
Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
... FMS-related tyrosine kinase 3; GiST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; HeS/CeL, hypereosinophilic syndrome/chronic eosinophilic leukemia; LvD, left ventricular dysfunction; ...
11
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
... BCR–ABL-targeted tyrosine-kinase inhibitors has led to greatly improved outcomes in patients with chronic myeloid leukemia, including high rates of complete hematologic, cytogenetic, and molecular ...
21
Chronic Myeloid Leukemia: How to Overcome the Tyrosine Kinase Inhibitors Resistance
... blood. Tyrosine kinase inhibitors (TKIs) has been the front-line therapy for CML by effectively inhibiting the BCR-ABL oncoprotein and achieved durable clinical responses in many ...
5
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment
... Abstract: Pulmonary hypertension is a disease with severe consequences for the human body. There are several diseases and situations that induce pulmonary hypertension and are usually underdiagnosed. Treatments include ...
11
New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
... © 2004 BioMed Central Ltd (Print ISSN 1465-5411; Online ISSN 1465-542X) Abstract Over the past several years many advances have been made in our understanding of critical pathways involved in carcinogenesis and tumor ...
7